China Pharma Holdings Inc (CPHI) Stock Analysis
Verdict: AVOID
A terminal revenue collapse paired with negative gross margins and a 0.27 current ratio makes this a high-risk liquidity trap.
Investment score: 12/100
Analysis as of
Is China Pharma Holdings Inc stock worth reviewing? The TradeMates thesis
China Pharma is a distressed micro-cap in a multi-year terminal decline. Avoid.
7-factor investment score
- Valuation: 15/100 (weight 20%)
- Financial Health: 5/100 (weight 15%)
- Technical Momentum: 30/100 (weight 15%)
- Earnings Quality: 5/100 (weight 15%)
- Insider Sentiment: 10/100 (weight 10%)
- Analyst Consensus: 0/100 (weight 10%)
- Risk-Adjusted Return: 10/100 (weight 15%)
China Pharma Holdings Inc opportunities and risks
What speaks for CPHI
- Volatility Trading Asset
What speaks against CPHI
- Imminent Insolvency / Liquidity Crunch
Peers and competitors
- 301331.SZ
- 3737.HK
- 8329.HK
- BGM
- 600276.SS
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| CPHI | n/a | 6.4x | n/a | -13.4% | -88.8% | 0.5% |
| BGM | n/a | 2.4x | 57.2x | 16.4% | -5.7% | -5.6% |
| Peer median | n/a | 2.4x | 57.2x | 16.4% | -5.7% | -5.6% |
Frequently asked questions about China Pharma Holdings Inc (CPHI)
Is CPHI stock a good investment?
The TradeMates model rates China Pharma Holdings Inc as AVOID with an investment score of 12/100. China Pharma is a distressed micro-cap in a multi-year terminal decline. Avoid. This is algorithmic model output, not personal investment advice.
Is CPHI stock a buy?
The TradeMates model verdict for CPHI is AVOID with an investment score of 12/100. Treat this as a model signal to review, not a personal buy recommendation.